12,605 Shares in Stryker Corporation $SYK Acquired by Oliver Luxxe Assets LLC

Oliver Luxxe Assets LLC bought a new stake in Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 12,605 shares of the medical technology company’s stock, valued at approximately $3,969,000.

A number of other institutional investors also recently added to or reduced their stakes in SYK. Everpar Advisors LLC raised its holdings in shares of Stryker by 73.4% in the 2nd quarter. Everpar Advisors LLC now owns 1,146 shares of the medical technology company’s stock valued at $361,000 after purchasing an additional 485 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in shares of Stryker by 4.1% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 12,844 shares of the medical technology company’s stock worth $4,044,000 after purchasing an additional 501 shares in the last quarter. Valeo Financial Advisors LLC grew its stake in shares of Stryker by 0.6% during the second quarter. Valeo Financial Advisors LLC now owns 6,475 shares of the medical technology company’s stock worth $2,039,000 after purchasing an additional 39 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. increased its holdings in Stryker by 2.4% in the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 3,103 shares of the medical technology company’s stock valued at $977,000 after buying an additional 74 shares during the last quarter. Finally, Trust Point Inc. increased its holdings in Stryker by 681.9% in the second quarter. Trust Point Inc. now owns 13,480 shares of the medical technology company’s stock valued at $4,244,000 after buying an additional 11,756 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 323,264 shares of company stock worth $100,659,489 in the last quarter. Company insiders own 4.60% of the company’s stock.

Stryker Stock Up 0.4%

SYK stock opened at $338.85 on Friday. The company has a market cap of $129.97 billion, a price-to-earnings ratio of 35.11, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76. The company has a fifty day moving average price of $320.11 and a 200 day moving average price of $334.13. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period last year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts expect that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Analyst Ratings Changes

A number of analysts have issued reports on SYK shares. Sanford C. Bernstein set a $410.00 price target on Stryker in a report on Friday, May 1st. Evercore set a $350.00 price objective on Stryker in a report on Monday, July 6th. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research report on Friday, May 1st. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Canaccord Genuity Group dropped their price target on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.